Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
BrightSpring Health Services Q4 2025 Earnings Call - Strong 2025 Growth, Balance Sheet Repair, and 2026 Guidance Despite $600M Pharmacy Revenue Headwind
BrightSpring closed 2025 with robust top-line and EBITDA growth, meaningful cash generation, and two strategic balance sheet moves that reshaped its near-term optionality. The company reported $12.9 b...
- BrightSpring reported full year 2025 revenue of $12.9 billion, up 28% year over year, and adjusted EBITDA of $618 million, up 34% year over year.
- Fourth quarter 2025 revenue was $3.6 billion, up approximately 29% year over year, and adjusted EBITDA for Q4 was $184 million, up 41% year over year.
- Operating cash flow for 2025 was $490 million, and Q4 cash flow was $232 million, supporting faster deleveraging and capital flexibility.
- +12 more takeaways
TTEC Fourth Quarter and Full Year 2025 Earnings Call - $205M Non-Cash Digital Goodwill Hit, but AI-First Pivot Aims to Lift Margins
TTEC closed 2025 with revenues roughly in line with guidance, $2.14 billion for the year, and improved profitability. Adjusted EBITDA rose to $214 million, free cash flow turned positive at $83 millio...
- Full-year 2025 revenue roughly $2.14 billion, slightly down year-over-year but above guidance high end on a GAAP basis.
- Adjusted EBITDA for 2025 was $214 million, up 5.6% year-over-year, and non-GAAP operating income rose to $155 million.
- A $193 million non-cash goodwill impairment was recorded in Q4 against the Digital recurring reporting unit, with an additional $12 million tax impact, for a total GAAP charge of $205 million.
- +12 more takeaways
LiqTech International Q4 FY2025 Earnings Call - Pivot to Standardized, Higher-Margin Systems After Oil & Gas Delay
LiqTech closed FY2025 with revenue of about $16.5 million, up 13% year over year, driven by a 49% jump in systems and aftermarket sales. Management used the quarter to draw a line under unpredictable,...
- FY2025 revenue roughly $16.5 million, up 13% from 2024.
- Systems and aftermarket sales jumped 49%, to $8.2 million in 2025, driving top-line growth.
- Record commercial pool performance: 34 pool systems sold in 2025, with 24 delivered and 10 backlogged for early 2026; pool revenue was $2.6 million.
- +14 more takeaways
Via Q4 2025 Earnings Call - Record Net New Platform Revenue, 30% Growth and Path to Profitability by Q4 2026
Via closed 2025 with another strong quarter, reporting Q4 platform revenue of $119 million, up 30% year over year, and the narrowest adjusted EBITDA loss in company history at negative 6% for Q4. Mana...
- Q4 platform revenue $119 million, up 30% year over year, marking the eighth consecutive quarter with 30%+ platform growth.
- 2025 platform revenue $434 million, up 31% year over year, with adjusted EBITDA improving to negative 8% for the year and Q4 adjusted EBITDA margin at negative 6% (lowest loss on record).
- Company reported the strongest quarter ever for net new platform revenue and ended Q4 with 821 customers after organically growing 9% year over year and adding 94 customers via the Downtowner acquisition.
- +12 more takeaways
Fulgent Genetics Q4 2025 Earnings Call - Largest Customer Moving In-House Forces 2026 Revenue Rebalance
Fulgent closed 2025 with revenue of $322.7 million, up 14% year over year, but Q4 showed the first visible crack. The company says its single largest customer, which generated $70.8 million or roughly...
- 2025 revenue totaled $322.7 million, up about 14% versus 2024; Q4 revenue was $83.3 million, down slightly sequentially.
- Largest customer contributed $70.8 million in 2025, or ~22% of revenue, and management expects that relationship to fall to about $11.8 million in 2026, a ~$59 million revenue hit.
- Company guidance for 2026 is approximately $350 million in total revenue, about 8.5% growth year over year, with revenue backloaded to H2.
- +13 more takeaways
Carter’s Inc. Q4 2025 Earnings Call - Tariffs Cloud Margins Even as D2C Momentum Restores Pricing Power
Carter’s finished 2025 with top-line momentum, reporting its first year-over-year revenue growth (excluding the extra 53rd week) since 2021 and its third consecutive quarter of comp gains, driven by D...
- Carter’s returned to year-over-year revenue growth in 2025 for the first time since 2021, even when excluding the 53rd week.
- Fourth quarter net sales were $925 million, up 8% year-over-year; on a comparable 13-week basis sales rose about 3%.
- Q4 gross margin was 43.2%, down 460 basis points year-over-year, with tariffs alone a roughly $40 million gross headwind in the quarter.
- +12 more takeaways
ALX Oncology Q4 2025 Earnings Call - CD47 Biomarker Validation Drives Evorpacept Strategy and Trial Expansion
ALX used the Q4 2025 call to cement a clear, biomarker-driven strategy for its lead asset evorpacept, citing convergent clinical signals that CD47 overexpression predicts powerful responses across HER...
- Company announced Barb Klencke as permanent Chief Medical Officer after interim role since September 2025, emphasizing clinical leadership continuity.
- Evorpacept (EVO) now has data from over 750 treated patients, and management says the antibody and bispecific combination MOA is clinically validated.
- Randomized Phase 2 gastric cancer subset with HER2-positive, CD47-overexpressing tumors showed a 65% response rate with evorpacept plus trastuzumab versus 26% control, median DOR over 2 years, median PFS 18.4 vs 7 months, hazard ratio 0.39, and median OS 17 vs ~10 months with HR 0.7.
- +13 more takeaways
Arcosa, Inc. Q4 2025 Earnings Call - Barge Sale Sharpens Focus, Utilities and Aggregates to Drive 2026 Growth
Arcosa closed 2025 with record revenue and profitability, then made a decisive portfolio move by agreeing to sell its barge business for $450 million, a deal expected to close in Q2 2026. Management p...
- Record 2025 financials: revenues $2.9 billion, Adjusted EBITDA $583 million, Adjusted EBITDA margin 20.2% (up 280 basis points).
- Company entered definitive agreement to sell barge business for $450 million in cash, expected to close in Q2 2026, buyer Wynnchurch Capital named by management.
- Post-divestiture strategy is focused squarely on construction materials and engineered structures, reducing portfolio complexity and cyclicality.
- +15 more takeaways
Amneal Pharmaceuticals Fourth Quarter 2025 Earnings Call - Launch wave and biosimilars to drive 2026-27 acceleration
Amneal closed 2025 with steady top and bottom line growth and a heavy roster of complex launches that management says will accelerate revenue in 2026 and 2027. Full year revenue reached about $3.0 bil...
- 2025 finish: Full year revenue roughly $3.0 billion, up 8%; adjusted EBITDA $688 million, up 10%; adjusted EPS $0.83, up 43%.
- Q4 specifics: Revenue $814 million, up 11%; adjusted EBITDA over $175 million, up 13%; Q4 EPS $0.21, up 75%.
- 2026 guidance: Revenue growth expected 1% to 4%, adjusted EBITDA up 5% to 10% ($720 million to $760 million), adjusted EPS $0.93 to $1.03, and operating cash flow $325 million to $375 million.
- +13 more takeaways
Natural Resource Partners L.P. Q4 2025 Earnings Call - $39M Sisecam Investment Delays Distribution Increase as Commodities Sit at Cyclical and Generational Lows
Natural Resource Partners reported resilient free cash flow despite brutal commodity markets, generating $46 million in Q4 and $169 million for full-year 2025. Management revised the timing of a plann...
- NRP generated $46 million of free cash flow in Q4 2025 and $169 million for full-year 2025, showing operational cash resilience despite weak commodity prices.
- Management elected to contribute $39 million of capital to the Sisecam Wyoming soda ash joint venture to reduce bank borrowings and shore up the JV, delaying planned distribution increases.
- Sisecam Wyoming has not paid distributions since Q2 2025, and NRP does not expect distributions to resume until soda ash demand rebounds or there is a significant supply response.
- +12 more takeaways